Preclinical models support a role for dopaminergic signaling in promoting myeloid cell trafficking into the CNS and inflammation, and blocking monocyte recruitment in PD models, especially CCR2+ subsets, has shown neuroprotective effects (39, 73–75). Here, CCR2 is linked to Parkinson disease.